Ultima Genomics Selected for Large-Scale Immune Profiling Study
Ultima Genomics' sequencing platform has been chosen for a major immune profiling study involving 80,000 blood samples, in collaboration with IMU Biosciences, UK Biobank, and Waters Corporation.
Ultima Genomics' UG200™ Sequencing Platform has been selected as a key component for a landmark, large-scale immune profiling study.
In collaboration with IMU Biosciences and UK Biobank, the study aims to generate an AI-driven foundational dataset for immune profiling. This dataset will be derived from 80,000 blood samples collected from UK Biobank participants, utilizing Waters Corporation's BD Rhapsody™ Single-Cell Platform.
The comprehensive study brings together experts in proteomics and immunology to create a dataset intended to deepen the understanding of the human immune system's function and its role in disease. The objective is to accelerate the development of new therapies.
Ultima Genomics' technology enables the generation of high-volume, cost-effective single-cell data, which is crucial for extensive biological research of this nature. The project is expected to yield valuable insights into disease mechanisms and facilitate the development of more precise diagnostic tools.